France· FR:60966449
REPATHA 140 mg, solution injectable en stylo prérempli
A evolocumab product containing évolocumab, registered in France by AMGEN EUROPE, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Evolocumab is registered in 15 of 19 countries.
Countries holding a registration under ATC C10AX13 (evolocumab), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Evolocumab · ATC C10AX13
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of evolocumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Evolocumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$17.24
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ÉVOLOCUMAB
- Manufacturer
- AMGEN EUROPE
- Country
- France (FR)
- ATC code
- C10AX13
- ATC class
- Evolocumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300285821 stylo prérempli en verre (SureClick) de 1 ml avec aiguille(s)EUR 183.97
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Evolocumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsRepatha 140 mg oplossing voor injectie in een voorgevulde penAmgen Europe B.V.
- IrelandRepatha 140 mg solution for injection in pre-filled penAmgen Europe B.V.
- United StatesREPATHAAmgen USA Inc.
- CzechiaREPATHAAmgen Europe B.V., Breda
- FinlandRepathaAmgen Europe B.V.
- IcelandRepathaAmgen Europe B.V.*
- SpainREPATHA 140 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAAmgen Europe B.V.
- SwedenRepatha 140 mg Injektionsvätska, lösning i förfylld injektionspennaAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Repatha
- Norway · Repatha
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/88e9f847-9e90-4964-8f52-9176b4cc4be6 GET /v1/drugs/88e9f847-9e90-4964-8f52-9176b4cc4be6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60966449",
"date_amm": "2015-07-17",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/15/1016",
"substance": "ÉVOLOCUMAB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about evolocumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.